Effect of funding source on reporting bias in studies of intravitreal anti‐vascular endothelial growth factor therapy for retinal vein occlusion

On research quality: proud to be co-author on some studies on @BayerPharma side & congrats also to @Regeneron, @Novartis and @genentech team: Anti-#Vegf studies for Ophtha showed no outcome reporting bias between industry and non-industry funding. 👏…